{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:12:57Z","timestamp":1786389177782,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.chc.2019.05.005","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:52:04Z","timestamp":1562028724000},"page":"583-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Psychotropic Medication for Children and Adolescents with Eating Disorders"],"prefix":"10.1016","volume":"28","author":[{"given":"Jennifer","family":"Couturier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna","family":"Isserlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Spettigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40519-016-0253-0","article-title":"Psychotropic medications in adult and adolescent eating disorders: clinical practice versus evidence-based recommendations","volume":"21","author":"Garner","year":"2016","journal-title":"Eat Weight Disord"},{"key":"10.1016\/j.chc.2019.05.005_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s40519-018-0520-3","article-title":"Psychotropic usage by patients presenting to an academic eating disorders program","author":"Mizusaki","year":"2018","journal-title":"Eat Weight Disord"},{"issue":"1","key":"10.1016\/j.chc.2019.05.005_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jadohealth.2015.03.021","article-title":"Use of psychopharmacologic medications in adolescents with restrictive eating disorders: analysis of data from the National Eating Disorder Quality Improvement Collaborative","volume":"57","author":"Monge","year":"2015","journal-title":"J\u00a0Adolesc Health"},{"issue":"5","key":"10.1016\/j.chc.2019.05.005_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaac.2015.01.018","article-title":"Practice parameter for the assessment and treatment of children and adolescents with eating disorders","volume":"54","author":"Lock","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2019.05.005_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/erv.2240","article-title":"Psychotropic drug treatment in anorexia nervosa. Search for differences in efficacy\/tolerability between adolescent and mixed-age population","volume":"21","author":"Balestrieri","year":"2013","journal-title":"Eur Eat Disord Rev"},{"issue":"4","key":"10.1016\/j.chc.2019.05.005_bib6","first-page":"173","article-title":"A\u00a0review of medication use for children and adolescents with eating disorders","volume":"16","author":"Couturier","year":"2007","journal-title":"J\u00a0Can Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2989\/17280583.2014.909816","article-title":"The psychopharmacological management of eating disorders in children and adolescents","volume":"26","author":"van den Heuvel","year":"2014","journal-title":"J\u00a0Child Adolesc Ment Health"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/cap.2010.0139","article-title":"A\u00a0placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa","volume":"21","author":"Kafantaris","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/10640261003719468","article-title":"Factors influencing research drug trials in adolescents with anorexia nervosa","volume":"18","author":"Norris","year":"2010","journal-title":"Eat Disord"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib10","first-page":"197","article-title":"Evaluation of the effectiveness and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescents: an open-label trial","volume":"27","author":"Spettigue","year":"2018","journal-title":"J\u00a0Can Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1089\/cap.2009.0072","article-title":"Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity","volume":"20","author":"Leggero","year":"2010","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/cap.2009.0098","article-title":"No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders","volume":"21","author":"Swenne","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.chc.2019.05.005_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.biopsych.2005.04.008","article-title":"Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?","volume":"58","author":"Hillebrand","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/cap.2010.0131","article-title":"Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa","volume":"21","author":"Norris","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.chc.2019.05.005_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/cap.2013.0124","article-title":"Second generation antipsychotics in adolescent anorexia nervosa: a new hypothesis of eligibility criteria","volume":"24","author":"Pisano","year":"2014","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib16","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1007\/BF03327760","article-title":"Olanzapine use in adolescent anorexia nervosa","volume":"11","author":"Dennis","year":"2006","journal-title":"Eat Weight Disord"},{"issue":"1","key":"10.1016\/j.chc.2019.05.005_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/eat.10115","article-title":"Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports","volume":"33","author":"Boachie","year":"2003","journal-title":"Int J Eat Disord"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s007870170039","article-title":"Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases","volume":"10","author":"Mehler","year":"2001","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/(SICI)1098-108X(200004)27:3<363::AID-EAT16>3.0.CO;2-5","article-title":"Case reports of olanzapine treatment of anorexia nervosa","volume":"27","author":"La Via","year":"2000","journal-title":"Int J Eat Disord"},{"issue":"6","key":"10.1016\/j.chc.2019.05.005_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1440-1819.2008.01881.x","article-title":"Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified","volume":"62","author":"Tateno","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"issue":"9","key":"10.1016\/j.chc.2019.05.005_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jaac.2011.06.009","article-title":"A\u00a0double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study","volume":"50","author":"Hagman","year":"2011","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2019.05.005_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00004583-199607000-00021","article-title":"Case study: anorexia nervosa and autistic disorder in an adolescent girl","volume":"35","author":"Fisman","year":"1996","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/erv.843","article-title":"Atypical antipsychotics in severe anorexia nervosa in children and adolescents\u2014review and case reports","volume":"16","author":"Mehler-Wex","year":"2008","journal-title":"Eur Eat Disord Rev"},{"issue":"1","key":"10.1016\/j.chc.2019.05.005_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/eat.20325","article-title":"Quetiapine in anorexia nervosa patients: an open label outpatient pilot study","volume":"40","author":"Powers","year":"2007","journal-title":"Int J Eat Disord"},{"issue":"5","key":"10.1016\/j.chc.2019.05.005_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/eat.22485","article-title":"Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa---a case series","volume":"49","author":"Frank","year":"2016","journal-title":"Int J Eat Disord"},{"issue":"4","key":"10.1016\/j.chc.2019.05.005_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/eat.22704","article-title":"The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa","volume":"50","author":"Frank","year":"2017","journal-title":"Int J Eat Disord"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/eat.20807","article-title":"Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports","volume":"44","author":"Trunko","year":"2011","journal-title":"Int J Eat Disord"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jpsychires.2004.08.001","article-title":"A\u00a0retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy","volume":"39","author":"Holtkamp","year":"2005","journal-title":"J\u00a0Psychiatr Res"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/cap.1999.9.195","article-title":"No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study","volume":"9","author":"Strober","year":"1999","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2019.05.005_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-2007-992145","article-title":"Serotonin-induced platelet intracellular Ca2+ response in patients with anorexia nervosa","volume":"41","author":"Wockel","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.chc.2019.05.005_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/eat.1048","article-title":"Sertraline in underweight binge eating\/purging-type eating disorders: five case reports","volume":"29","author":"Frank","year":"2001","journal-title":"Int J Eat Disord"},{"issue":"6","key":"10.1016\/j.chc.2019.05.005_bib32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/00004583-199011000-00031","article-title":"Fluoxetine and anorexia","volume":"29","author":"Lyles","year":"1990","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.chc.2019.05.005_bib33","first-page":"375","article-title":"Obsessive-compulsive disorder and anorexia nervosa in a high school athlete: a case report","volume":"34","author":"Gee","year":"1999","journal-title":"J\u00a0Athl Train"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00787-007-0670-8","article-title":"Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study","volume":"17","author":"Hrdlicka","year":"2008","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2019.05.005_bib35","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1080\/00048670701517983","article-title":"Mirtazapine for anorexia nervosa with depression","volume":"41","author":"Jaafar","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2019.05.005_bib36","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1097\/MJT.0000000000000613","article-title":"An adolescent male with anorexia nervosa favorably responded to mirtazapine","volume":"25","author":"Naguy","year":"2018","journal-title":"Am J Ther"},{"issue":"8","key":"10.1016\/j.chc.2019.05.005_bib37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/00004583-200008000-00002","article-title":"Risperidone in anorexia nervosa","volume":"39","author":"Newman-Toker","year":"2000","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2019.05.005_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hup.492","article-title":"Olanzapine treatment of an adolescent girl with anorexia nervosa","volume":"18","author":"Ercan","year":"2003","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"10.1016\/j.chc.2019.05.005_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/104454603322572660","article-title":"An open trial of fluoxetine for adolescents with bulimia nervosa","volume":"13","author":"Kotler","year":"2003","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.chc.2019.05.005_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/erv.877","article-title":"Treatment emergent mania responding to valproate in a Chinese female adolescent population with eating disorders: a case series","volume":"16","author":"Tor","year":"2008","journal-title":"Eur Eat Disord Rev"},{"issue":"4","key":"10.1016\/j.chc.2019.05.005_bib41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jwh.2005.14.345","article-title":"Bulimia nervosa and attention deficit hyperactivity disorder: a possible role for stimulant medication","volume":"14","author":"Dukarm","year":"2005","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.chc.2019.05.005_bib42","first-page":"20","article-title":"Treatment of children and adolescents with avoidant\/restrictive food intake disorder: a case series examining the feasibility of family therapy and adjunctive treatments","volume":"6","author":"Spettigue","year":"2018","journal-title":"J\u00a0Eat Disord"},{"issue":"10","key":"10.1016\/j.chc.2019.05.005_bib43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1089\/cap.2017.0133","article-title":"Adjunctive use of olanzapine in the treatment of avoidant restrictive food intake disorder in children and adolescents in an eating disorders program","volume":"27","author":"Brewerton","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.chc.2019.05.005_bib44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/cap.2013.0149","article-title":"Lorazepam in the treatment of posttraumatic feeding disorder","volume":"24","author":"Kardas","year":"2014","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.chc.2019.05.005_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/cap.2015.0145","article-title":"Mirtazapine for choking phobia: report of a pediatric case","volume":"25","author":"Tanidir","year":"2015","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/cap.2017.0162","article-title":"Escitalopram in the treatment of a 3-year-old child with posttraumatic feeding disorder","volume":"28","author":"Hosoglu","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/cap.2006.0057","article-title":"Fluoxetine in posttraumatic eating disorder in two-year-old twins","volume":"17","author":"Celik","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.chc.2019.05.005_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004703-200504000-00008","article-title":"Use of low-dose selective serotonin reuptake inhibitors for severe, refractory choking phobia in childhood","volume":"26","author":"Banerjee","year":"2005","journal-title":"J\u00a0Dev Behav Pediatr"},{"issue":"4","key":"10.1016\/j.chc.2019.05.005_bib49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/WNF.0000000000000288","article-title":"Phagophobia successfully treated with low-dose aripiprazole in an adolescent: a case report","volume":"41","author":"Colak Sivri","year":"2018","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"10.1016\/j.chc.2019.05.005_bib50","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/eat.22602","article-title":"Severe avoidant\/restrictive food intake disorder and coexisting stimulant treated attention deficit hyperactivity disorder","volume":"49","author":"Pennell","year":"2016","journal-title":"Int J Eat Disord"},{"issue":"6","key":"10.1016\/j.chc.2019.05.005_bib51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/cap.2018.0005","article-title":"Buspirone treatment of anxiety in an adolescent female with avoidant\/restrictive food intake disorder","volume":"28","author":"Okereke","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2019.05.005_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000194641","article-title":"Diagnostic crossover from obesity to atypical anorexia nervosa---a case report","volume":"2","author":"Wolter","year":"2009","journal-title":"Obes Facts"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499319300574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499319300574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:47:22Z","timestamp":1761000442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499319300574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1056499319300574"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2019.05.005","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychotropic Medication for Children and Adolescents with Eating Disorders","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2019.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}